By Kenneth Lim
Boston, May 18 - Hong Kong's Lijun International Pharmaceutical (Holding) Co. Ltd. sold RMB 160 million of three-year zero-coupon convertible unsubordinated unsecured bonds to yield 3.875% with an initial conversion premium of 2.98%.
The convertibles were offered at par.
ABN Amro was the bookrunner of the Regulation S offering.
The convertibles are non-callable and may not be put.
The convertibles have dividend and takeover protection.
Lijun, a Hong Kong-based pharmaceutical manufacturer, said the proceeds of the deal will be used to fund acquisitions, investments or joint ventures.
| Issuer: | Lijun International Pharmaceutical (Holding) Co. Ltd.
|
| Issue: | Convertible unsubordinated unsecured bonds
|
| Bookrunner: | ABN Amro
|
| Amount: | RMB 160 million
|
| Greenshoe: | None
|
| Maturity: | May 30, 2010
|
| Coupon: | 0%
|
| Price: | Par
|
| Redemption price: | 121.1547%
|
| Yield: | 3.875%
|
| Conversion premium: | 2.98%
|
| Conversion price: | HK$4.15
|
| Dividend protection: | Yes
|
| Takeover protection: | Yes
|
| Call protection: | Non-callable
|
| Puts: | None
|
| Pricing date: | May 14
|
| Settlement date: | May 30
|
| Distribution: | Regulation S
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
